<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183166</url>
  </required_header>
  <id_info>
    <org_study_id>TG4050.02</org_study_id>
    <nct_id>NCT04183166</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating TG4050 in Head and Neck Cancer</brief_title>
  <official_title>A Randomized Phase I Trial in Patients With Newly Diagnosed, Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Evaluating a Mutanome-directed Immunotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, two arms, randomized, phase I study evaluating the safety&#xD;
      and tolerability as well as some activity parameters of TG4050 in patients with squamous cell&#xD;
      carcinoma of the head and neck (SCCHN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (Adverse Event reported per CTCAE v5)</measure>
    <time_frame>Up to 2 Years.</time_frame>
    <description>Incidence of Adverse Event reported per CTCAE v5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival duration</measure>
    <time_frame>Up to 2 Years.</time_frame>
    <description>Time from documented Complete Response after primary treatment to date of first recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Percentage of patients whose best overall response is either a Complete Response or a Partial Response according to RECIST version 1.1 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <arm_group>
    <arm_group_label>Arm A : Early study treatment initiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG4050 treatment initiation at completion of primary treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Study treatment initiation at recurrence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TG4050 treatment initiation at the time of recurrence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG4050</intervention_name>
    <description>Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks</description>
    <arm_group_label>Arm A : Early study treatment initiation</arm_group_label>
    <arm_group_label>Arm B: Study treatment initiation at recurrence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Newly diagnosed stage III or IVA squamous-cell carcinoma of the oral cavity,&#xD;
             oropharynx, hypopharynx or larynx&#xD;
&#xD;
          3. Female or male patients, aged at least 18 years&#xD;
&#xD;
          4. Patients in Complete Response after treatment of their primary tumor.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          6. Adequate hematological, hepatic and renal functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with carcinoma of the nasopharynx, squamous cell-carcinoma of unknown&#xD;
             primary, squamous cell carcinoma that originates from the skin and salivary gland or&#xD;
             paranasal sinus, non-squamous histologies.&#xD;
&#xD;
          2. Prior exposure to cancer immunotherapy including anti-cancer vaccines, any antibody&#xD;
             targeting T-cell co-regulatory proteins such as anti-PD1, anti-PDL1 or anti-CTLA4&#xD;
             antibodies.&#xD;
&#xD;
          3. Other active malignancy requiring concurrent systemic intervention.&#xD;
&#xD;
          4. Patients with previous malignancies other than the target malignancy to be&#xD;
             investigated in this trial&#xD;
&#xD;
          5. Known history of positive testing for Human Immunodeficiency Virus (HIV) or known&#xD;
             Acquired Immune Deficiency Syndrome (AIDS)&#xD;
&#xD;
          6. Clinical or laboratory history or evidence of Hepatitis C Virus (HCV) or Hepatitis B&#xD;
             Virus (HBV) indicating acute or chronic infection&#xD;
&#xD;
          7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test (&gt; 10 mIU/mL)&#xD;
&#xD;
          8. Treatment with another investigational agent within 30 days prior to TG4050 treatment&#xD;
             initiation&#xD;
&#xD;
          9. Uncontrolled intercurrent illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Transgene EU, Clinical Operations Department</last_name>
    <phone>+ 33.3.88.27.91.00</phone>
    <email>clinical.trials@transgene.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr Le Tourneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr Delord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHS Clatterbridge Cancer Center</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Sacco</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pr Ottensmeier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital NHS Fondation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pr Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital NHS Fondation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Karydis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

